Literature DB >> 6273025

Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.

A N Elias, G Gwinup, L J Valenta.   

Abstract

Two patients with Nelson's syndrome and one patient after bilateral adrenalectomy for Cushing's disease, without any evidence of Nelson's syndrome, were studied with respect to the effect of hydrocortisone, naloxone and valproic acid (a GABA transaminase inhibitor) on ACTH secretion. Hydrocortisone suppressed plasma ACTH concentrations to normal in the patient without Nelson's syndrome, but failed to do so in the two patients with Nelson's syndrome. Naloxone and valproic acid caused a decline in plasma ACTH concentrations in the patients with Nelson's syndrome, but produced no change in the patient without Nelson's syndrome. Secretion of ACTH may thus be influenced by both opiate peptide and by gamma aminobutyric acid, as well as by the cortisol concentration, these agents may act at different sites to inhibit ACTH release by the tumour.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273025     DOI: 10.1111/j.1365-2265.1981.tb00649.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Effects of sodium-valproate administration on plasma ACTH levels in patients with ACTH hypersecretion.

Authors:  B Ambrosi; D Bochicchio; E Riva; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256

3.  The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.

Authors:  M Reincke; B Allolio; D Kaulen; C Jaursch-Hancke; W Winkelmann
Journal:  Klin Wochenschr       Date:  1988-08-01

4.  Cannabinoids and their interactions with diazepam on modulation of serum corticosterone concentration in male mice.

Authors:  Ali Saber-Tehrani; Nima Naderi; Azadeh Hosseini Najarkolaei; Abbas Haghparast; Fereshteh Motamedi
Journal:  Neurochem Res       Date:  2009-07-10       Impact factor: 3.996

5.  Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.

Authors:  P Loli; M E Berselli; F Frascatani; F Muratori; M Tagliaferri
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

6.  Fever of unexplained origin, biochemical Cushing's disease and cerebral dysrhythmia corrected by valproate sodium.

Authors:  J M López-Moreno; J A Rodríguez-Portales; D Mahana
Journal:  Can Med Assoc J       Date:  1985-01-15       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.